Compare Nebius Group NV (NBIS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Vertex Pharmaceuticals Incorporated — how do they compare? Nebius Group NV trades at $236.45 (market cap $66.30B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2× Nebius Group NV's market cap. Which is the better fit depends on your goals.
| NBIS | VRTX | |
|---|---|---|
Market Cap | $66.30B | $134.06B |
Sector | Technology | Health |
52-Week High | $286.69 | $557.96 |
52-Week Low | $73.87 | $376.62 |
Enterprise Value | $68.43B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS stock surged 7.73% to $243.88 following a strategic partnership announcement with Palantir as its preferred sovereign AI infrastructure partner. The stock trades near its pivot point of $244 with bullish technical indicators and strong analyst support (80% buy ratings). Despite high valuation multiples (P/E 74.61, P/S 49.83), the company shows improving earnings trends with recent quarterly beats and projected revenue growth from $530M to $1.4B in 2026.
The outlook remains positive with a consensus price target of $291.33 (19% upside), driven by AI infrastructure demand and the Palantir partnership. Key risks include stretched valuations, negative operating cash flow relative to investments, and execution challenges in scaling capacity. The stock presents growth potential but requires careful monitoring of profitability improvements and contract execution.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
